THURSDAY, Oct. 31, 2024 (HealthDay News) -- Inavolisib plus palbociclib-fulvestrant yields significantly longer ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

In MBC, Kisqali has consistently demonstrated statistically significant overall survival benefit ... menopausal patients with HR+/HER2- advanced breast cancer. Further, Kisqali in combination with ...

A powerful three-drug therapy for aggressive advanced breast ... mutant HR-positive breast cancer. The results show that inavolisib in combination with palbociclib and fulvestrant significantly ...

NICE has recommended moving Novartis’ Kisqali (ribociclib ... negative advanced breast cancer who had previous endocrine therapy. This compared patients treated with Kisqali plus fulvestrant ...

et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine ...

Induction chemotherapy followed by chemoradiotherapy improves five-year progression-free and overall survival rates in locally advanced cervical cancer patients. The induction chemotherapy regimen led ...

Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer ...

In the trial, Kisqali plus endocrine ... significant overall survival benefit across three Phase III trials16-26. The NCCN Guidelines® for breast cancer recommend ribociclib (Kisqali) as the ...